Venetoclax chemo combo active and well-tolerated in children with r/r AML
Venetoclax chemo combo active and well-tolerated in children with r/r AML
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma
CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma
Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma
Multiple myeloma highlights from ASH 2019
Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML
Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results
Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data
Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions